Timothy R. Wilson

9.0k citations

88 papers · 4.3k indexed · 1 hit paper · h-index 32

Molecular Biology top 5%
Oncology top 1%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 2%
Genetics top 2%

Co-authors: Jeff Settleman Daniel B. Longley Patrick G. Johnston Mark Merchant Mark R. Lackner David J. Alexander Leeona Galligan Hartmut Koeppen
Topics: PI3K/AKT/mTOR signaling in cancer (26 papers)Advanced Breast Cancer Therapies (18 papers)Cancer Genomics and Diagnostics (16 papers)
Cited by: Oncology Cancer Research Genetics
Journals: Nature Nature Communications Journal of Clinical Oncology
Partner nations: United States United Kingdom France

In The Last Decade

Timothy R. Wilson

86 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Timothy R. Wilson, Jane Fridlyand et al. profile →

Peers

Countries citing papers authored by Timothy R. Wilson

Since Specialization

Citations

This map shows the geographic impact of Timothy R. Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy R. Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy R. Wilson more than expected).

Fields of papers citing papers by Timothy R. Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy R. Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy R. Wilson. The network helps show where Timothy R. Wilson may publish in the future.

Co-authorship network of co-authors of Timothy R. Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy R. Wilson. A scholar is included among the top collaborators of Timothy R. Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy R. Wilson. Timothy R. Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Community groups, organisations, and employers respond to the challenges of the Covid-19 pandemic: A story of resilience and continued vulnerability 2025 ·BMC Public Health ·Katharine Abba,Adele Ring,Peter Lloyd,Rachel Anderson de Cuevas,Shaima Hassan,Mark Goodall,(unknown),Kerry Hanna,(unknown),(unknown),(unknown),Alan D. Price,(unknown),Timothy R. Wilson,(unknown),Kerry Woolfall,Mark Gabbay	2
2	Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. 2024 ·Journal of Clinical Oncology ·Rafał Dziadziuszko,Fabrice Barlési,Jeong Eun Kim,Shirish M. Gadgeel,Maciej Krzakowski,Jae Ho Jeong,Gennaro Daniele,David Chen,Youyou Hu,Timothy R. Wilson,Brian Simmons,David M. Thomas	0
3	ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes 2023 ·Molecular Oncology ·Jessica W. Chen,William Jacot,Javier Cortés,Ian E. Krop,Susan Dent,Nadia Harbeck,Michelino De Laurentiis,Véronique Dièras,Young‐Hyuck Im,Thomas J. Stout,Frauke Schimmöller,Heidi Savage,Katherine E. Hutchinson,Timothy R. Wilson	1
4	Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations 2023 ·Clinical Cancer Research ·Smruthy Sivakumar,Dexter X. Jin,(unknown),Jeffrey S. Ross,Lewis C. Cantley,Maurizio Scaltriti,Jessica W. Chen,Katherine E. Hutchinson,Timothy R. Wilson,Ethan Sokol,Neil Vasan	16
5	Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial 2022 ·EBioMedicine ·DeAnna Friedman-Klabanoff,Megan Birkhold,(unknown),Timothy R. Wilson,Claudio Meneses,Joshua R. Lacsina,Fabiano Oliveira,Shaden Kamhawi,Jesús G. Valenzuela,Sally Hunsberger,Allyson Mateja,Gregory Stoloff,Olga Pleguezuelos,Matthew J. Memoli,Matthew B. Laurens	15
6	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer 2021 ·Journal of Clinical Oncology ·Rafał Dziadziuszko,Matthew Krebs,Filippo de Braud,Salvatore Siena,Alexander Drilon,Robert C. Doebele,Manish Patel,Byoung Chul Cho,Stephen V. Liu,Myung‐Ju Ahn,Chao‐Hua Chiu,Anna F. Farago,Chia‐Chi Lin,Christos S. Karapetis,Yu Li,Bann‐Mo Day,David Chen,Timothy R. Wilson,Fabrice Barlési	111
7	Binding of Leishmania infantum Lipophosphoglycan to the Midgut Is Not Sufficient To Define Vector Competence in Lutzomyia longipalpis Sand Flies 2020 ·mSphere ·Iliano V. Coutinho-Abreu,(unknown),(unknown),Timothy R. Wilson,Claudio Meneses,Rodrigo Pedro Soares,Valéria M. Borges,Albert Descoteaux,Shaden Kamhawi,Jesús G. Valenzuela	5
8	1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib 2020 ·Annals of Oncology ·Rafał Dziadziuszko,Fabrice André,Wesley Yip,(unknown),Joel Skoletsky,Rebecca Woodhouse,Tsung‐Hsing Hung,Timothy R. Wilson,Todd Riehl,(unknown),(unknown)	4
9	Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial 2020 ·Annals of Oncology ·Susan Dent,Javier Cortés,Young‐Hyuck Im,Véronique Dièras,Nadia Harbeck,Ian E. Krop,Timothy R. Wilson,Na Cui,Frauke Schimmöller,Jerry Y. Hsu,Jie He,Michelino De Laurentiis,Susana Sousa,Pamela Drullinsky,William Jacot	116
10	The longitudinal NIHR ARC North West Coast Household Health Survey: exploring health inequalities in disadvantaged communities 2020 ·BMC Public Health ·Clarissa Giebel,Jason C. McIntyre,Ana Alfirevic,Rhiannon Corcoran,Konstantinos Daras,Jennifer Downing,Mark Gabbay,Munir Pirmohamed,Jennie Popay,(unknown),(unknown),Timothy R. Wilson,Richard P. Bentall,Ben Barr	11
11	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models 2019 ·Molecular Cancer Therapeutics ·Heather M. Moore,Heidi Savage,Carol O’Brien,Wei Zhou,Ethan S. Sokol,Michael E. Goldberg,Ciara Metcalfe,Lori S. Friedman,Mark R. Lackner,Timothy R. Wilson	8
12	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer 2019 ·Breast Cancer Research and Treatment ·Vandana G. Abramson,Mafalda Oliveira,Andrés Cervantes,Hans Wildiers,Manish R. Patel,Todd M. Bauer,Philippe L. Bédard,Carlos Becerra,Stephen Richey,Michael C. Wei,Eric L. Reyner,John H. Bond,Na Cui,Timothy R. Wilson,Heather M. Moore,Cristina Saura,Ian E. Krop	4
13	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Maura N. Dickler,Cristina Saura,Donald Richards,Ian E. Krop,Andrés Cervantes,Philippe L. Bédard,Manish R. Patel,Lajos Pusztai,Mafalda Oliveira,(unknown),Na Cui,Timothy R. Wilson,Thomas J. Stout,Michael C. Wei,Jerry Y. Hsu,José Baselga	57
14	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. 2018 ·Journal of Clinical Oncology ·José Baselga,Susan Dent,Javier Cortés,Young‐Hyuck Im,Véronique Dièras,Nadia Harbeck,Ian E. Krop,Sunil Verma,Timothy R. Wilson,Huan Jin,Lijia Wang,Frauke Schimmöller,Jerry Y. Hsu,Jing He,Michelino De Laurentiis,Pamela Drullinsky,William Jacot	105
15	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers 2018 ·Molecular Cancer Research ·Timothy R. Wilson,Akshata R. Udyavar,Ching‐Wei Chang,Jill M. Spoerke,Junko Aimi,Heidi Savage,Anneleen Daemen,Joyce O’Shaughnessy,Richard Bourgon,Mark R. Lackner	15
16	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors 2017 ·Cancer Discovery ·Dejan Juric,Ian E. Krop,Ramesh K. Ramanathan,Timothy R. Wilson,Joseph A. Ware,Sandra Sanabria Bohórquez,Heidi Savage,Deepak Sampath,Laurent Salphati,Ray Lin,Huan Jin,Hema Parmar,Jerry Y. Hsu,Daniel D. Von Hoff,José Baselga	120
17	The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation 2014 ·Cancer Research ·Debasish Raha,Timothy R. Wilson,Jing Peng,David Peterson,Yue Peng,Marie Evangelista,Catherine Wilson,Mark Merchant,Jeff Settleman	223
18	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples 2014 ·Breast Cancer Research and Treatment ·Timothy R. Wilson,Yuanyuan Xiao,Jill M. Spoerke,Jane Fridlyand,Hartmut Koeppen,(unknown),Ling Huw,(unknown),(unknown),Erica Schleifman,Rupal Desai,Ling Fu,Teiko Sumiyoshi,Joyce O’Shaughnessy,Garret M. Hampton,Mark R. Lackner	21
19	Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers 2011 ·Cancer Cell ·Timothy R. Wilson,Diana Lee,Leanne Berry,David S. Shames,Jeff Settleman	125
20	Interleukin-8/CXCR2 signaling plays an important role in conferring resistance of prostate cancer cells to chemotherapy 2007 ·Molecular Cancer Therapeutics ·Catherine Wilson,Timothy R. Wilson,Patrick Johnston,Daniel B. Longley,David Waugh	2

About Timothy R. Wilson

Timothy R. Wilson is a scholar working on Oncology, Cancer Research and Genetics, having authored 88 papers that have together received 4.3k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (26 papers), Advanced Breast Cancer Therapies (18 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (2.2k citations), Cancer Research (961 citations) and Genetics (373 citations). Timothy R. Wilson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Jeff Settleman, Daniel B. Longley, Patrick G. Johnston, Mark Merchant, Mark R. Lackner, David J. Alexander, Leeona Galligan, Hartmut Koeppen, Yulei Wang and Miranda McEwan. Their work appears in journals such as Nature, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact